Some studies have linked high GREM1 expression to poor prognosis in several malignancies, including ER-negative breast cancer [16], cervical cancer [61], ex-trahepatic cholangiocarcinoma [62], basal cell carcinoma [63] and renal cell carcinoma [64]. Here, GREM1 is linked to basal cell carcinoma.